CDC - After FDA approves and ACIP recommends a COVID-19 booster dose, the goal is for those who received their shots in the earlier phases of vaccine rollout to get their booster
![ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine | Australian Government Department of Health and Aged Care ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine | Australian Government Department of Health and Aged Care](https://www.health.gov.au/sites/default/files/styles/h_content_max_width_no_upscale/public/images/news/2022/03/atagi-statement-on-recommendations-on-a-winter-booster-dose-of-covid-19-vaccine.jpeg?itok=n_5-xKUD)
ATAGI statement on recommendations on a winter booster dose of COVID-19 vaccine | Australian Government Department of Health and Aged Care
![Vaccines | Free Full-Text | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes? Vaccines | Free Full-Text | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?](https://www.mdpi.com/vaccines/vaccines-08-00227/article_deploy/html/images/vaccines-08-00227-g001-550.jpg)
Vaccines | Free Full-Text | Is There Any Opportunity to Provide an HBV Vaccine Booster Dose before Anti-Hbs Titer Vanishes?
HSE Ireland - If you have a weak immune system you'll need a booster dose three months after your last COVID-19 vaccine. For most people this will mean your booster dose will
![Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR](https://www.cdc.gov/mmwr/volumes/70/wr/social-media/mm7050e2_BoostersAdditionalPrimaryDoses_IMAGE_10Dec21_1200x627.jpg?_=35384)
Booster and Additional Primary Dose COVID-19 Vaccinations Among Adults Aged ≥65 Years — United States, August 13, 2021–November 19, 2021 | MMWR
![Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA](https://www.fda.gov/files/Booster%20Infographic_D_Rev_010622_0.png)
Coronavirus (COVID-19) Update: FDA Shortens Interval for Booster Dose of Moderna COVID-19 Vaccine to Five Months | FDA
![The COVID-19 Green Alert Level to be re-adopted as the lowest alert level within the COVID-19 Alert Level Traffic Light System from 3 September | The official website for the latest health The COVID-19 Green Alert Level to be re-adopted as the lowest alert level within the COVID-19 Alert Level Traffic Light System from 3 September | The official website for the latest health](https://www.moh.gov.bh/Content/Upload/Image/637648384281099609-D8C7E030-81C8-4D05-830C-C0877B5DF2AA.jpeg)
The COVID-19 Green Alert Level to be re-adopted as the lowest alert level within the COVID-19 Alert Level Traffic Light System from 3 September | The official website for the latest health
![Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet](https://www.thelancet.com/cms/attachment/55458d8a-6e53-43a3-abb0-e72e5acba138/gr1.gif)
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study - The Lancet
![Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41591-022-01832-0/MediaObjects/41591_2022_1832_Fig1_HTML.png)
Effectiveness of a second BNT162b2 booster vaccine against hospitalization and death from COVID-19 in adults aged over 60 years | Nature Medicine
![Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN](https://media.cnn.com/api/v1/images/stellar/prod/221024193034-covid-19-booster-090922.jpg?c=original)
Updated Covid-19 boosters offer protection, but new studies suggest they don't offer an edge against Omicron | CNN
![Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR](https://www.cdc.gov/mmwr/volumes/71/wr/social-media/mm7148e1-BivalentBooster_IMAGE_22NOV2022_1200x675.jpg?_=65732)
Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR
![Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ... Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...](https://www.cdc.gov/mmwr/volumes/72/wr/social-media/mm7205e1_BivalentVECurrentSublineages_IMAGE_25Jan2023_1200x675-medium.jpg?_=95835)
Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5– and XBB/XBB.1.5–Related Sublineages Among Immunocompetent Adults — Increasing Community Access to Testing ...
![Booster Shots and Additional Doses for COVID-19 Vaccines — What You Need to Know | Johns Hopkins Medicine Booster Shots and Additional Doses for COVID-19 Vaccines — What You Need to Know | Johns Hopkins Medicine](https://www.hopkinsmedicine.org/-/media/images/health/1_-conditions/coronavirus/booster-hero.jpg?h=500&iar=0&mh=500&mw=1300&w=1297&hash=347BF4C0B6A9B79B1BD52AF5F53E5AEC)